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Abstract
Rapamycin is an anticancer agent and immunosuppressant that acts by inhibiting the TOR signaling pathway. In yeast,
rapamycin mediates a profound transcriptional response for which the RRD1 gene is required. To further investigate this
connection, we performed genome-wide location analysis of RNA polymerase II (RNAPII) and Rrd1 in response to rapamycin
and found that Rrd1 colocalizes with RNAPII on actively transcribed genes and that both are recruited to rapamycin
responsive genes. Strikingly, when Rrd1 is lacking, RNAPII remains inappropriately associated to ribosomal genes and fails to
be recruited to rapamycin responsive genes. This occurs independently of TATA box binding protein recruitment but
involves the modulation of the phosphorylation status of RNAPII CTD by Rrd1. Further, we demonstrate that Rrd1 is also
involved in various other transcriptional stress responses besides rapamycin. We propose that Rrd1 is a novel transcription
elongation factor that fine-tunes the transcriptional stress response of RNAPII.
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Introduction
Rapamycin is an immunosuppressant and an anticancer
molecule that acts through inhibition of the TOR (target of
rapamycin) signaling pathway [1]. In the yeast Saccharomyces
cerevisiae, TOR1 and TOR2 encode serine/threonine kinases that
form the core of the rapamycin sensitive (TORC1) and the
rapamycin insensitive (TORC2) complex, respectively [2,3].
TORC1 positively regulates anabolic processes by promoting
mRNA translation and the transcription of ribosome biogenesis
genes [2,3]. Upon nutrient starvation or rapamycin treatment, the
TORC1 complex becomes inactivated, with the consequence of a
severe reduction of anabolic processes, cell cycle progression and
growth, as well as the induction of catabolic processes and stress
responsive factors [2,3]. These drastic changes are driven by
important alterations of gene transcription mediated, at least in
part, by the translocation of transcription factors to the nucleus.
Upon TORC1 inhibition, the ribosomal gene repressor, Crf1,
translocates into the nucleus to inhibit ribosomal gene transcrip-
tion [4]. Furthermore, the TORC1 regulator Tap42 activates
PP2A and Sit4 phosphatases, which in turn dephosphorylate the
transcription factors Rtg1/2 and Gln3 causing them to move into
the nucleus and induce the expression of retrograde signalling
genes (RTG) and nitrogen discrimination genes (NDG), respec-
tively [2,5,6,7]. Once translocated into the nucleus, these
transcription factors bind to specific DNA elements, alter the
local chromatin state and recruit the general transcription
machinery to mediate pre-initiation complex (PIC) assembly and
transcription by RNAPII [8,9].
The exact mechanisms of these regulatory circuits are not fully
understood but genome wide deletion screens in S.cerevisae have
been a useful tool to identify novel factors that are required to
mediate an efficient response to rapamycin [10,11,12,13]. One of
these factors is the peptidyl prolyl isomerase Rrd1 (Resistant to
rapamycin deletion 1). Rrd1D mutants exhibit multiple phenotypes
including sensitivity to the carcinogen 4-nitroquinoline-1-oxide
and UVA radiation, and, most prominently, extreme resistance to
rapamycin [13]. Rrd1 is evolutionally conserved and shares 35%
identity with its human homologue PTPA [14]. PTPA was first
characterized to be an activator of the phospho-tyrosyl phospha-
tase activity of PP2A phosphatases in vitro [15,16]. However, an in
vivo role for this activity has not yet been described, and subsequent
studies revealed that PTPA as well as Rrd1 are required for PP2A
substrate specificity, complex formation and the reactivation of
inactive PP2A complexes [17,18]. Both were later found to possess
intrinsic peptidyl prolyl isomerase activity on a specific PP2A
peptide [14]. Consistent with this function, we and others found
that Rrd1 interacts with the yeast PP2A-like phosphatase Sit4 [19].
Sit4 and Rrd1 form a ternary complex with the Tor signaling
mediator Tap42 [19]. As mentioned above, upon TORC1
inactivation Tap42 dissociates from Sit4-Rrd1, which then
dephosphorylates and activates the transcription factor Gln3
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23159[6,20]. However, we found that the Gln3 target gene MEP2 was
activated independently of Rrd1, suggesting that this latter factor
has an additional role in the response to rapamycin [20].
Consistent with this, we found that Rrd1 exerts an effect at the
transcriptional level: genes known to be upregulated (the diauxic
shift genes CPA2 and PYC1) and down-regulated (the ribosomal
protein genes including RPS26A, RPL30, and RPL9) following
rapamycin exposure showed an altered transcription pattern in
rrd1D mutants [20]. Since ribosomal biogenesis results from the
concerted action of all three RNA polymerases, which are
controlled by a tight regulatory network, we expected that Rrd1
plays a broader role in transcription of these genes [21]. Indeed,
we subsequently found that Rrd1 is associated with the chromatin
and that it interacts with the major subunit of RNAPII [22].
Further, biochemical analysis revealed that Rrd1 is able to release
RNAPII from the chromatin in vivo and in vitro, which we ascribed
to the peptidyl prolyl isomerase activity acting on the C-terminal
domain (CTD) of RNAPII [22]. This mechanism of RNAPII
regulation resembles that of the peptidyl prolyl isomerase, Pin1,
and its yeast homologue Ess1 which are also known to regulate
transcription [23,24,25,26,27]. Both Pin1 and Ess1 are thought to
isomerize the CTD of RNAPII and regulate elongation [26,27]. In
yeast, the CTD consists of 26 repeats of the YS2PTS5PS7 heptad
sequence which are differentially phosphorylated on Ser2, Ser5
and Ser7 [28,29,30,31]. These different phosphorylation patterns
act as a recruitment platform for multiple factors involved in
chromatin remodelling, mRNA processing and transcription
termination [28,29,30,31]. For example, Ess1 has been shown to
stimulate the dephosphorylation of Ser5 to efficiently terminate
transcription of a subset of genes [24].
In this study, we analyzed how Rrd1 regulates transcription by
RNAPII. We mapped Rrd1 and RNAPII occupancy using ChIP-
chip analysis in the presence and the absence of rapamycin. We
found that Rrd1 colocalized with RNAPII on actively transcribed
genes under both conditions. Furthermore, rrd1D deletion affected
RNAPII occupancy on a large set of rapamycin responsive genes.
This was independent of TATA binding protein (TBP) recruit-
ment to the promoter, suggesting that Rrd1 acts downstream of
PIC formation during transcriptional initiation and elongation.
The observation that Rrd1 modulated Ser5 and Ser2 phosphor-
ylation of the RNAPII CTD further supported a role for Rrd1 in
elongation. Finally, we demonstrate that Rrd1 is required to
regulate gene expression in response to a variety of environmental
stresses, thus establishing Rrd1 as a new elongation factor required
for effective transcriptional responses to environmental challenges.
Results
Rrd1 affects RNAPII occupancy on rapamycin responsive
genes
Recently, we have shown that Rrd1 interacts with and
isomerizes RNA polymerase II (RNAPII) in response to rapamycin
[22]. Also it was demonstrated that Rrd1 is required to regulate
the expression of some rapamycin responsive genes [20]. To
further investigate this, we used ChIP analysis to measure the
association of Rpb1, the major subunit of RNAPII (henceforth
referred to as RNAPII), within the ORFs of four known
rapamycin-responsive genes in wild-type cells and rrd1D mutant
cells [32]. The rapamycin-upregulated genes, such as HSP104 and
PUT4, were significantly enriched for RNAPII in the wild-type
strain, but this association was reduced in the rrd1D mutant
(Fig. 1A and B). Examination of RPL32 and RPS2, which are
downregulated by rapamycin, revealed that RNAPII dissociated
from both genes upon rapamycin treatment of wild-type yeast but
remained bound in the rrd1D (Fig. 1A and B). Localization of
RNAPII to ACT1, a gene unaffected by rapamycin treatment, was
not altered upon addition of rapamycin in wild-type cells and or by
RRD1 deletion (Fig. 1A and B). These data indicate that Rrd1 is
required to modulate expression of a larger set of genes than
previously discovered [20].
To better understand by what mechanism Rrd1 affects
transcription, we tagged Rrd1 with a Myc epitope and asked if
Rrd1 also localizes to the set of genes assayed above. Similar to
RNAPII, Rrd1 occupancy was increased on the ORFs of HSP104
and PUT4, depleted on those of RPL32 and RPS2, and remained
constant on ACT1, in response to rapamycin (Fig. 1C). These data
suggest that Rrd1 directly regulates these rapamycin-responsive
genes.
Rrd1 localization correlates with RNAPII along actively
transcribed genes
To extend our initial analysis from a small set of genes to the
entire genome, we used the ChIP-chip assay to examine the
genome-wide distribution of both RNAPII and Rrd1. We first
examined RNAPII occupancy under exponential growth condi-
tions and after a 30 minutes treatment with rapamycin, the time
point at which the rapamycin transcriptional response is most
prominent based on mRNA expression analysis [32]. ChIP
samples were hybridized on tiling arrays covering the whole yeast
genome with an average resolution of four probes per kilobase. We
first calculated the median RNAPII occupancy over the coding
region of approximately 5000 ORFs and clustered these
enrichment values using self organizing maps (SOM) with Cluster
3.0 and used Java TreeView to visualize the data [33]. Figure 2A
shows the average RNAPII signal over each ORF in the absence
(column 1), or the presence (column 2) of rapamycin. In order to
better visualize the genes that were affected by rapamycin, we also
show the difference in RNAPII occupancy between the two
conditions (rapamycin treated data was subtracted from the
untreated; column 3). We identified 6 clusters of genes (W1–W6)
with different behaviors upon rapamycin treatment. These clusters
were then analyzed for gene ontology (GO) category using
funcassociate 2.0 (Fig. 2B and Suppl. File S1) [34]. This analysis
revealed that upon rapamycin treatment, RNAPII occupancy was
sharply reduced on metabolic genes including those involved in
ribosome biogenesis (see cluster W1, W6 and Fig. 2B). In contrast,
RNAPII was strongly recruited to genes involved in nitrogen
discrimination, the Krebs cycle, stress response and catabolic
processes after rapamycin treatment (W3, W4 and Fig. 2B). These
data are consistent with the transcriptional changes reported for
rapamycin treatment as well as for environmental stress responses
[32,35].
We next performed ChIP-chip analysis on Myc-tagged Rrd1
and compared its distribution on the ORFs with that of RNAPII.
As shown in Figure 2C, RNAPII occupancy correlates with that of
Rrd1, indicating that Rrd1 is recruited to transcribed genes.
Interestingly, when cells were treated with rapamycin, Rrd1 and
RNAPII displayed a similar correlation (Suppl. Fig S1A),
suggesting that under normal growth conditions, as well as after
drastic transcriptional changes, Rrd1 remains associated to
actively transcribed genes. To further investigate this relationship,
we mapped RNAPII occupancy along a group of genes with the
lowest levels of RNAPII as well as a group with the highest levels of
RNAPII and then mapped Rrd1 on the same groups (Fig. 2D).
Indeed, when RNAPII levels were low, the Rrd1 levels were also
low, and consistently, when RNAPII levels were high Rrd1 levels
were also increased (Fig. 2D). This was also the case for rapamycin
treated cells (Suppl. Fig. S1B).
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with RNAPII in response to rapamycin, we plotted the difference
in RNAPII occupancy between untreated and rapamycin-treated
cells versus the difference in Rrd1 occupancy between these two
conditions (Fig. 2E). This analysis revealed that both, Rrd1 and
RNAPII are downregulated on a large group of genes and
recruited to another group of genes in response to rapamycin
(R
2=0.34). Taken together, this data suggest that Rrd1 and
RNAPII co-localize on the coding region of most of the actively
transcribed genes, even after massive transcriptional changes such
as the ones caused by rapamycin treatment.
RRD1 is required for proper RNAPII relocalization in
response to rapamycin
Since Rrd1 co-localizes with RNAPII on actively transcribed
genes and Rrd1 was previously shown to be required to modulate
the expression of a few rapamycin-responsive genes [20], we
analyzed the genome-wide localization of RNAPII in the rrd1D
mutant. To compare RNAPII levels from the wild-type and rrd1D
cells, we plotted RNAPII occupancy in wild-type and rrd1D cells,
both in absence and presence of rapamycin (Fig. 3A). Whereas
RNAPII levels were similar (R
2=0.87) in untreated cells, they
were less correlated in response to rapamycin (R
2=0.75),
suggesting that Rrd1 is required to regulate RNAPII occupancy
in response to rapamycin as observed at individual genes in
figure 1. To further confirm this, we mapped RNAPII occupancy
from wild-type and rrd1D mutant on the six clusters from Figure 2A
(Fig. 3B). Interestingly, at down regulated genes, RNAPII in the
rrd1D mutant failed to reach levels as low as in wild type cells
(cluster W1 and W6). On the other hand, on upregulated genes
(cluster W3 and W4) RNAPII also failed to reach wild-type levels
in the rrd1D mutant. We note that RNAPII occupancy was similar
for the untreated RNAPII levels (full line) as well as for clusters
that were not affected by rapamycin (cluster W2 and W5). Taken
Figure 1. Rrd1 affects RNAPII occupancy on rapamycin responsive genes. (A) ChIP of Rpb1 (RNAPII) from WT cells followed by Q-PCR on the
indicated genes. Dashed bars indicate rapamycin treatment (100 ng/ml for 30 min). The data is represented as a ratio of the % IP over Input on the
ORF compared to % IP over Input in a non transcribed region (noORF). (B) ChIP of RNAPII from rrd1D mutant cells performed as in panel A. (C) ChIP of
Rrd1-MYC (Myc antibodies) performed as in panel A. Results for all panels are shown as an average of at least three independent experiments, error
bars indicate the standard deviation and the asterix (*) indicates if the P-value is below 0.05 between the untreated and treated condition using the
Student T test.
doi:10.1371/journal.pone.0023159.g001
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optimal up and down regulation of RNAPII levels during
rapamycin response.
Rrd1 regulates RNAPII occupancy independently of TBP
binding
To find out at what step Rrd1 influences RNAPII transcription,
we examined the genome wide association of the yeast Myc-tagged
TATA box binding protein (TBP) encoded by SPT15 using ChIP-
chip. If, upon rapamycin treatment, Rrd1 affects steps upstream of
PIC formation, TBP occupancy would be affected in rrd1D cells. In
the other scenario, whereby Rrd1 was to affect a step downstream
from PIC formation (such as elongtion for example), TBP levels
(contrarily to RNAPII levels, Figure 3B) would not necessarily be
affected. We therefore mapped TBP occupancy in WT (blue) and
rrd1D cells (orange) on genes from clusters W1–W6 (Fig. 4A).
Interestingly, at upregulated genes (cluster W3 and W4) TBP
binding (unlike RNAPII occupancy) is not affected by the deletion
Figure 2. Rrd1 localization correlates with RNAPII along actively transcribed genes. (A) Self-organizing map (SOM) clustering analysis of
the median enrichment of RNAPII on all ORFs from the WT strain. The red colour indicates enriched (bound) regions and blue colour represents
depleted regions. The difference (diff (+/2)) (right column) was calculated by subtracting the complete untreated (2RAP) RNAPII data set (left
column) from the treated (+RAP) RNAPII data set (middle row) (RAP=rapamycin 100 ng/ml for 30 min). The brackets (W1–W6) indicate clusters that
were analyzed by gene ontology (GO). (B) Functional annotation of cluster W1–W6 with representative GO groups is shown. Funcassociate 2.0 was
used to generate the full GO analysis, available in supplemental file S1. The X- axis represents the P-value. (C) Linear correlation of RNAPII and Rrd1-
Myc enriched genes under normal growth condition. Each dot represents a single gene containing the median enrichment value from RNAPII on the
y-axis and the Rrd1-Myc median enrichments on the x-axis. For the rapamycin treated data sets refer to supplemental figure S1A. (D) Mapping of
RNAPII and Rrd1 on groups of genes with different median enrichment of RNAPII under normal growth conditions. The red line represents RNAPII
along the 10% of genes with the highest amount of RNAPII and the blue line represents Rrd1 on this same group of genes. The orange line represents
RNAPII on the lowest 10% RNAPII enriched genes and the green line represents Rrd1 on this same group of genes. (E) Linear correlation of RNAPII and
Rrd1 gene occupancy differences between normal growth and rapamycin conditions. This is the same analysis as (C) only that the difference of the
untreated and treated data set for the median enrichment of RNAPII and Rrd1 was plotted.
doi:10.1371/journal.pone.0023159.g002
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PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23159Figure 3. rrd1D deletion affects RNAPII localization in response to rapamycin. (A) Linear correlation of RNAPII median enrichment of WT (x-
axis) and rrd1D mutant (y-axis) under normal growth conditions (2RAP) (left panel) and rapamycin treated conditions (+RAP) (right panel). The trend
line and the R
2 value are displayed for each condition. (B) Mapping of RNAPII from WT cells (green line) and rrd1D mutant cells (red line) under normal
growth conditions (full line) and rapamycin treated conditions (dotted line) on cluster W1–W6 from figure 2A. Mappings are sorted for unaffected
genes (green) upregulated genes (red) and downregulated genes (blue).
doi:10.1371/journal.pone.0023159.g003
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controlled by Rrd1 independently of TBP binding and suggest
that Rrd1 may regulate transcriptional elongation as will be
addressed below.
We next checked if the regulation of the rapamycin-downreg-
ulated genes by Rrd1 is TBP-independant. Preliminary analysis of
the downregulated genes (clusters W1 and W6) suggested that
these are heterogeneous with respect to TBP binding (Fig. 4A). We
therefore generated new clusters from clusters W1 and W6 using
both RNAPII and TBP occupancy values from wild type cells
(Fig. 4B). This clustering revealed that although RNAPII is
downregulated for all genes TBP occupancy is only reduced in
cluster S2 and S3 in wild-type cells treated with rapamycin. This
suggests that, in wild-type cells, rapamycin leads to gene
expression downregulation by at least two distinct mechanisms.
The first involving the regulation of TBP recruitment and the
latter involving the regulation of a downstream step. To look at the
function of Rrd1 in that regulation, we looked at TBP and
RNAPII occupancies in rrd1D cells on these clusters (Figure 4C).
As predicted from Figure 4A, deletion of RRD1 affected RNAPII
occupancy of all these genes upon rapamycin treatment.
Interestingly, however, TBP levels were not affected by the
deletion of RRD1 for the genes included in clusters S1 and S4,
while they were significantly crippled at genes from clusters S2 and
S3. Taken together these data indicate that RNAPII downregu-
lation upon rapamycin treatment is regulated by two mechanisms,
one which does not depend on TBP depletion (cluster S1 and S4).
Interestingly, Rrd1 is required for both mechanisms by optimizing
TBP depletion (S2 and S3) and RNAPII levels (S1 and S4). This
suggests that Rrd1 has an influence on TBP binding, probably by
affecting the signaling cascade upstream of PIC assembly [19] but
also functions downstream of TBP binding, likely during
transcription initiation/elongation.
Rrd1 functions during transcription elongation
The above data suggest that Rrd1 might regulate RNAPII
during transcription initiation and/or elongation. To test this
possibility we used a well known transcription elongation assay
that is based on an artificial arrest site (ARTAR) within the E.coli
b- galactosidase ORF and is thought to cause RNAPII stalling/
pausing downstream of the promoter during elongation [25,36].
This ARTAR is composed of three arrest sites which promote
backtracking and arresting of RNAPII and elongation factors such
as Dst1 are required to restart RNAPII so that it can resume
transcription [25,36]. We introduced this reporter gene expression
plasmid in the wild-type, rrd1D mutant and dst1D mutant strains
and measured LacZ expression (Fig. 5A). Similar to wild-type,
rrd1D mutants were able to overcome the ARTAR and express
LacZ as opposed to the dst1D mutants, suggesting that Rrd1 is not
essential to overcome RNAPII arrests in this system. We next
tested whether increased dosage of Rrd1 would rescue the
elongation defect of dst1D mutants (Fig. 5A). Strikingly, ectopic
overexpression of Rrd1 partially restored the lacZ expression in
the dst1D mutant. This clearly indicates that although Rrd1 is not
essential for transcription elongation it is likely to perform a
backup function during elongation or alternatively that Rrd1
promotes elongation of RNAPII in such a way that it overcomes
the ARTAR.
Many mutants defective in transcription elongation, such as
dst1D and spt4D, are known to be sensitive to 6-azauracil (6-AU),
an inhibitor of the IMP dehydrogenase, which decreases GTP
pools and thereby causes transcriptional arrest [36]. We found that
rrd1D mutants were sensitive to 6-AU, although not as sensitive as
dst1D cells (Fig. 5B), further supporting a role for Rrd1 in
transcription elongation.
Finally, we examined whether Rrd1 might influence elongation
by altering the phosphorylation status of the RNAPII C-terminal
domain (CTD). The CTD is highly phosphorylated on Ser5 at the
promoter and in the early elongation phase, and is progressively
dephosphorylated as transcription progresses. In contrast, Ser2
phosphorylation gradually increases throughout the ORF, reach-
ing maximum levels at the 39 end of the gene [28,29,30,31]. These
differential phosphorylation states can be used to monitor
transcription elongation efficiency [24,27]. We used phosphospe-
cific antibodies to perform ChIP-chip analysis for Ser5 phosphor-
ylation (Ser5-P) and Ser2 phosphorylation (Ser2-P) in wild-type
and rrd1D strains with and without rapamycin. Figure 5C shows
the correlation between wild-type and rrd1D for Ser5-P and Ser2-P
under untreated and rapamycin treated conditions. The correla-
tion of Ser2-P shifted from a R
2=0.89 to an R
2=0.68 upon
rapamycin treatment and the correlation of Ser5-P was even more
affected upon treatment (R
2=0.84 and R
2=0.53). This suggests
that Rrd1 influences the phosphorylation status of RNAPII in
response to rapamycin. We next mapped Ser5-P and Ser2-P from
wild-type and rrd1D mutant on clusters W1 to W6 (Fig. 5D and
Suppl. Fig. S2A). We found that in general the pattern of Ser5-P
and Ser2-P is similar between wild-type and rrd1D mutant under
normal growth condition (full line). However, when treated with
rapamycin (dashed line) the patterns of both phosphorylations
were altered in the rrd1D mutant in each cluster, leading to an
increase in the 39 region of the genes. On down regulated genes,
Ser5-P largely remained at the 39end in the mutant as compared
to wild-type for cluster W1 and increased for cluster W6 (Fig. 5D).
In the case of the upregulated genes (W3 and W4), Ser5-P
increased in the wild-type at promoters and within the ORF but
not in the mutant where it remained low except for being elevated
at the 39 end of these genes. Similarly to Ser5-P, Ser2-P remained
high at the 39 end of genes in the mutant on down regulated genes
(W1 and W6). Also for the upregulated genes, Ser2-P was lower in
the mutant throughout the ORFs but then peaked only at the 39
end as compared to wild-type (W3 and W4). We next analyzed
Ser5-P and Ser2-P on the clusters S1 to S4 and here also, both
phosphorylations were similarly altered in response to rapamycin
(Suppl. Fig S2B). Taken together, this indicates that Rrd1 affects
the phosphorylation states of RNAPII in response to a transcrip-
tional stress (see discussion).
Rrd1 plays a role in environmental stress responses
The above data indicate that Rrd1 is required for an optimal
transcriptional response following rapamycin exposure. Since
rapamycin mimics nutrient starvation conditions, we next asked
whether Rrd1 is required for optimal response to other
Figure 4. Rrd1 is required for RNAPII association independently of TBP recruitment. (A) Mapping of TBP-MYC occupancy on genes from
clusters W1–W6, from WT (blue) and from rrd1D mutant (orange) under normal growth condition (full line) and rapamycin treatment (dotted line). (B)
SOM clustering of cluster W1 and W6 of RNAPII under normal growth conditions (2RAP), the difference of RNAPII from treated and untreated
conditions (diff) and the difference of TBP from treated and untreated conditions (diff). The red colour indicates enriched (bound) regions and blue
colour represents depleted regions. (C) Mapping analysis of the clusters S1–S4 generated from (A) of TBP (left panel) and RNAPII (right panel). Legend
is the same as (A) for TBP and the same as Fig. 3B for RNAPII.
doi:10.1371/journal.pone.0023159.g004
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mutants exhibit multiple phenotypes including resistance to
caffeine, but sensitivity towards vanadate, 4-NQO and calcium
[13,37]. Both vanadate and 4-NQO are known to cause oxidative
stress [37,38]. To test whether Rrd1 is required for resistance to
other oxidizing agents, we challenged cells with hydrogen peroxide
(H2O2) and sodium arsenite (NaAs) and found that the rrd1D
mutant was indeed sensitive to these agents (Fig. 6A and B). To
determine whether the sensitivity was the result of a defect in gene
regulation, we introduced a known arsenite-response reporter that
bears the promoter of the ACR3 gene fused to lacZ [39]. ACR3
encodes a plasma membrane efflux pump that is upregulated via
the Yap8 transcriptional activator in response to arsenite [39].
While there was a strong induction of the ACR3-lacZ reporter in
the wild-type, it was hardly induced in the rrd1D mutant (Fig. 6C).
This data suggests that the transcriptional response to oxidative
stress is also affected in the rrd1D mutant.
To explore this further, we monitored expression of 10 stress
responsive genes using the GeXP multiplex PCR system in
response to rapamycin, H2O2, NaAs and heat shock (see Materials
and Methods). We chose genes that are known to be upregulated
(PRX1, ARR3, HSP12, HXK1 and TSL1) or downregulated (RPL3,
RPL32, and RPS2) in response to environmental stresses as well as
control genes which are not significantly altered under these
conditions (ACT1, GAL1) [35]. The Kanamycin resistance marker
was added to the samples and used to normalize the data (see
materials and methods). First, the untreated and rapamycin-
treated expression data was compared to the RNAPII median
enrichment on these ORFs (see Suppl. Fig. S3). This analysis
revealed that for both conditions RNAPII occupancy correlated
with mRNA expression for all of the genes except the ribosomal
genes (see Suppl. Fig. S3). This can be explained by the mRNA
half life of the downregulated genes: Although RNAPII is depleted
from these genes, mRNA is still present. We next compared gene
expression in wild-type and rrd1D yeast for each condition (Fig. 7).
Genes that are known to be induced were indeed upregulated in
wild-type, but this was inhibited in the rrd1D mutant (Fig. 7A).
Genes that are known to be downregulated upon stress were
unaffected by RRD1 deletion (Fig. 7B). It might be possible that for
these genes other regulatory mechanisms are active such as the
above mentioned mRNA half life (see discussion). This is
consistent with the observation that RNAPII was strongly depleted
from these genes in response to rapamycin, but mRNA levels
remained unchanged (Suppl. Fig. S3). Finally, the control genes
ACT1 and GAL1 remained similar between wild-type and rrd1D
throughout the various conditions (Fig. 7C). Taken together, the
expression analysis and the multiple phenotypes of rrd1D mutants
towards environmental stresses suggest that the role of Rrd1 is not
limited to rapamycin, but instead that this peptidyl-prolyl
isomerase plays a general role in transcriptional stress responses.
Discussion
We have previously shown that Rrd1 is associated to chromatin
and interacts with RNAPII [22]. Consistently with this, we now
demonstrate that Rrd1 directly co-localizes with RNAPII on
actively transcribed genes independently of the massive transcrip-
tional changes that are induced by rapamycin. Interestingly, our
Figure 6. rrd1D mutants display hypersensitivity to agents
causing oxidative stress. (A) Survival curve of WT (open circle) and
rrd1D mutant strains (closed circle) upon H2O2 treatment. H2O2
concentrations are indicated below; result shown is an average of
three independent experiments and error bars indicate the standard
deviation. (B) Spot test analysis of WT and rrd1D mutant strain on YPD
agar plates, containing 1 mM sodium arsenite (NaAs), where indicated.
(C) LacZ reporter expression analysis from the ACR3 promoter-lacZ
fusion plasmid, expressed in Miller units. WT (open circle) and rrd1D
mutant (closed circle) show the lacZ expression over time in response
to 1 mM NaAs treatment (n=5).
doi:10.1371/journal.pone.0023159.g006
Figure 5. rrd1D mutants exhibit phenotypes consistent with a defect in transcriptional elongation. (A) Transcription elongation assay
measuring the b-galactosidase activity of the lacZ gene containing the artificial arrest site expressed from a plasmid transformed into the indicated
strains. The dst1D mutant strain was co-transformed with a plasmid expressing RRD1 (pRRD1). The measurements are expressed as Miller units and
are displayed as the average of at least 5 independent assays with the corresponding error bars. (B) Spot test analysis of WT, rrd1D and dst1D mutant
strains on agar containing selective media lacking uracil (URA) and containing 6-azauracil (6AU) with the indicated concentration. (C) Linear
correlations of the mean enrichment of Ser5 phosphorylated form of RNAPII (Ser5-P) at all promoters and Ser2 phosphorylated form of RNAPII (Ser2-
P) of all ORFs, between WT and rrd1D mutant without (2 RAP) and with (+ RAP) rapamycin treatment. (D) Mapping analysis of Ser5-P and Ser2-P
forms of RNAPII for up and downregulated genes in response to rapamycin. WT cells (green line) and rrd1D mutant cells (red line) under normal
growth conditions (full line) and rapamycin treated conditions (dotted line).
doi:10.1371/journal.pone.0023159.g005
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the body of the ORFs, since it reached its highest levels
downstream of the promoter as compared to RNAPII. In addition,
at the 39 gene ends Rrd1 occupancy was reduced before RNAPII.
Numerous other elongation factors such as Dst1 (TFIIS) were also
found to interact with RNAPII and to be associated within the
body of the gene [40,41]. These co-localisation events occurring
only during elongation suggest a function of Rrd1 during this
phase of transcription. This is further supported by the fact that
rrd1D deletion affects RNAPII gene occupancy in response to
rapamycin for up and down regulated genes. It is noteworthy that
this effect is noticeable during elongation, as the alterations of
RNAPII are visible within the body of the gene as opposed to
accumulation at the promoter or 39 end region. This implies that
Rrd1 regulates the amount of transcribing RNAPII, which could
be through at least two different mechanisms; one by recruiting
more RNAPII to these genes or two, by regulating the speed by
which RNAPII is transcribing along the genes.
Our analysis of TBP occupancy indicated that Rrd1 acts
upstream as well as downstream of TBP association and thus
might be involved in the recruitment as well as the regulation of
RNAPII elongation (Figure 4). Upon rapamycin treatment,
transcription factors translocate to the nucleus and are recruited
to promoters to stimulate or repress transcription by regulating
TBP and PIC assembly [4,5,8,42,43,44]. How Rrd1 might operate
upstream of TBP is unclear, although it could be through the
ability of Rrd1 to activate phosphatases [17,18,45]. For example,
Rrd1 could regulate a specific phosphatase thereby altering the
recruitment of transcription factors and PIC assembly. We note
that TBP remained promoter-bound on a subset of down
regulated genes from which RNAPII dissociated in response to
rapamycin. This was partially dependent on Rrd1 since RNAPII
was less drastically reduced in the rrd1D mutant (Fig. 4C cluster S1
and S4). This could be a mechanism to temporarily downregulate
transcription, while allowing for rapid restart of gene expression
once the stress is over. That Rrd1 influences a larger number of
genes downstream of PIC assembly suggests that this is the major
role of Rrd1 in the transcriptional response to rapamycin. This,
and given that Rrd1 is associated within the ORF of most genes,
indicates that it acts at the level of elongation. Also, although Rrd1
is constantly associated with RNAPII, deletion of RRD1 has only a
tangible effect on RNAPII in response to stress, meaning that
under normal growth conditions Rrd1 is not crucial for RNAPII
recruitment to genes. There are several more evidences advocating
that Rrd1 acts on RNAPII during initiation and/or elongation: (i)
We have previously shown that Rrd1 is localized to the chromatin,
Figure 7. mRNA expression analyses in response to different stress conditions. GeXP multiplex expression analysis of 10 genes from
untreated, rapamycin (100 ng/ml for 30 min), H2O2 (0.6 mM for 30 min), NaAs (1 mM for 30 min), heat shock (37uC for 30 min) treated conditions.
The data is expressed in log 2 ratio and is calculated relative to an internal PCR control. (A) Five upregulated genes. (B) Three downregulated genes
(C) Two control genes.
doi:10.1371/journal.pone.0023159.g007
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CTD in response to rapamycin [22]. Many transcription
elongation factors are known to interact with and modify the
CTD, including Pin1, Fcp1 and the Bur kinases and the CTD is
thought to be a recruitment platform for elongation, RNA
processing and termination factors [28,29,30,31]. (ii) Here we
have shown that overexpression of RRD1 suppresses the
elongation defect of DST1 (TFIIS) deletion in an artificial
elongation assay (ARTAR). Dst1 is crucial to transcribe this
ARTAR as it is required to restart paused RNAPII [25,36].
Although we currently cannot explain how RRD1 increased
dosage rescues the dst1D deficiency, we presume that this might be
via its function during elongation. (iii) Rrd1D mutants displayed
hypersensitivity against the agent 6-AU, a phenotype which is
common for elongation factors although it was not as sensitive as
dst1D mutants, possibly because Rrd1 affects elongation at only a
subset of genes whereas Dst1 acts globally [36,40,46,47,48,49].
Finally, (iv) rrd1D mutants displayed an altered phosphorylation
pattern for Ser5-P and Ser2-P on most genes (Fig. 5D and Suppl.
Fig. S2). Phosphorylation of RNAPII changes throughout
elongation and this pattern is altered in the rrd1D mutant. First
of all, the phosphorylation pattern appears to be similar under
normal growth conditions correlating with RNAPII levels.
However, one observes a distinctive pattern of Ser5-P and Ser2-
P in both up and downregulated genes in response to rapamycin.
In the rrd1D mutant Ser5-P and Ser2-P are strongly enriched in
the 39 region of the genes consistently throughout all up and down
regulated genes. So, how can the same phenomenon account for
the failure to up and down regulate gene expression? This may be
explained by the fact that for upregulated genes Ser5-P and Ser2-P
is much higher in the WT throughout the ORF but not at the 39
end of the gene compared to the rrd1D mutant. In this case, rrd1D
fail to up regulate CTD phosphorylation and thus RNAPII levels
do not increase. For down regulated genes rrd1D mutants retain
the altered phosphorylation patterns at the 39 end of the genes
thereby prohibiting an adequate downregulation of RNAPII.
Thus, Rrd1 would be required to modulate the phosphorylation of
RNAPII so that they remain flexible for up and down regulation.
If Rrd1 affects the phosphorylation status of RNAPII one would
expect to see changes in the global phosphorylation status of
RNAPII, for example analyzed by Western blot on total cell
extract. However, we previously monitored the total phosphory-
lation status of RNAPII in response to rapamycin in the rrd1D
mutant and could not find any significant differences [22]. This
apparent discrepancy can be explained by the fact that the
phosphorylation changes are very local (at the 39 end of genes) and
that for example, for the upregulated genes there is less
phosphorylation in the rrd1D mutant in the ORF but then retains
a higher level of phosphorylation in the 39-end of downregulated
genes. These subtle changes are therefore unlikely to be visible
using the immunoblot approaches.
We propose a model in which Rrd1 regulates elongation by
modulating the level of Ser5-P and Ser2-P via isomerisation of the
CTD of RNAPII. The isomerization of the CTD of RNAPII
would allow the efficient up and downregulation of RNAPII on
stress regulated genes. Our model has some precedent, as another
peptidyl-prolyl isomerase, Ess1, has been shown to regulate Ser5-P
of RNAPII at the end of snRNAs genes, thereby promoting
transcription termination via the Nrd1 pathway [24]. In addition,
over expression of Pin1 (the human homolog of Ess1) results in
hyper phosphorylation of RNAPII and its release from the
chromatin [27]. It is known that RNAPII occupancy is regulated
during transcription elongation, for example, it was previously
reported that RNAPII was enriched on ribosomal genes but
associated with a slow transcriptional rate [50]. Interestingly, when
these cells were transferred from glucose to galactose containing
medium, the level of RNAPII decreased on these ribosomal genes
and their transcriptional rate increased. Simultaneously, RNAPII
was recruited to other genes including those involved in
mitochondrial function [50]. Similar to a switch from glucose to
galactose, rapamycin induces a transcriptional response which
requires some genes to be turned off and others to be induced.
Rrd1 might promote this transcriptional reorganization by
allowing Ser5-P and Ser2-P changes thereby fine-tuning the
elongation efficiency.
Based on our model, we predicted that Rrd1 might play a
similar role in other stress response situations, notably the
environmental stress responses that induce a similar pattern of
gene expression as rapamycin [35,51]. Indeed, rrd1D mutants are
sensitive to agents that cause oxidative stress, which is known to
induce a drastic transcriptional response (Fig. 6) [35,51]. Although
these phenotypes may at first glance seem opposite of the one
observed for rapamycin, they are actually consistent with our
model of Rrd1 function: In both cases, the response to the stress
condition is inhibited in rrd1D cells. This leads to resistance to
rapamycin (because the environment remains nutrient-rich despite
the presence of the drug), but sensitivity to oxidative stress (because
the cells fail to arrest and adapt to high ROS conditions). In
accordance with this, we show that Rrd1 is required to adequately
induce gene expression on a subset of stress responsive genes upon
various stress conditions (Fig. 7). Surprisingly, ribosomal genes
were not strongly downregulated in wild-type cells as predicted
from the ChIP-chip data. Since mRNA levels were measured at 30
min, long mRNA half-lives could obscure the drop in transcription
that was apparent in the ChIP-chip data. Rrd1 was required for
induction of stress-induced genes, however, consistent with our
model. Interestingly, rrd1D cells showed stronger defects for some
stresses than others. For example, HSP12 induction was dependent
on Rrd1 after rapamycin and H2O2, but not heat shock and to a
lesser extend with NaAs (Fig. 7). This might be due to effects
specific to each condition, as not all of the genes we tested were
induced in the same manner by each condition. For example, the
NaAs exporter ACR3 was only expressed in response to NaAs, and
this was dependent on Rrd1 despite the fact that expression was
specific to one condition (Fig. 7).
Taken together, we have shown that Rrd1 regulates the
transcriptional stress response via two mechanisms, through
regulationof PICassembly,and more drastically through regulation
of RNAPII elongation. The latter mechanism is likely to be via
CTD isomerisation and alteration of the phosphorylation status of
RNAPII, thereby regulating the elongation of RNAPII. This is a
general stress response mechanism since rrd1D mutants display
multiple phenotypes and are unable to adequately regulate gene
expression in response to environmental changes. As such, we
propose that Rrd1 is a novel transcription elongation factor
required to modulate the expression in response to environmental
stresses. This study goes along with many others as it further
supports that elongation is also subject to transcriptional regulation.
Finally, as Rrd1 is conserved throughout evolution, future work
should examine whether this function is also remaining in higher
eukaryotes as this could be a potential target for the TOR
signalling pathway and cancer treatment.
Materials and Methods
Strains, cell growth and crosslinking conditions
All strains used in this study were from the BY4741 background
(Mat a, his3-1, leu2-0, met15-0, ura3-0). The RRD1 and SPT15 genes
Rrd1 Regulates Elongation of RNA Polymerase II
PLoS ONE | www.plosone.org 11 August 2011 | Volume 6 | Issue 8 | e23159were endogenously tagged as previously described [39]. For ChIP
analysis cells were grown in 50 mL of YPD to an OD600 of 0.6–0.8
before crosslinking with 1% formaldehyde for 30 min.
Chromatin Immunoprecipitation and Antibodies
ChIP experiments were performed as per [52], with minor
modifications. For myc-tag ChIP, we used 5 mg of 9E11 antibody
coupled to 2610
7 pan-mouse IgG DynaBeads (Invitrogen) per
sample. RNAPII ChIPs were done using 2 mL of 8WG16 antibody
coupled to 2610
7 panmouse IgG DynaBeads per sample. For
Ser2-P and Ser5-P ChIP, we used 100 mL of rat serum (3E8 and
3E10 respectively) coupled to 2610
7 protein G DynaBeads per
sample [53].
The microarrays used for location analysis were purchased from
Agilent Technologies (Palo Alto, California, United States) and
contain a total of 44,290 Tm-adjusted 60-mer probes covering the
entire genome for an average density of one probe every 275 bp
(6100 bp) within the probed regions (4X44K). Myc-tag ChIPs
were hybridized against ChIPs from isogenic strains that did not
contain the tag as controls. RNAPII ChIPs were hybridized
against a sample derived from 400 ng of input (non-immunopre-
cipitated) DNA.
Quantitative real-time PCR analysis was performed using the
ABI 7000 machine (Applied biosciences) and Sybr green PCR
mastermix (Applied biosystems). The % IP ORF/% IP no ORF
ratio was determined using the relative efficiency method and
calculated as in Lloyd et al. [54]. Primers were designed using the
primer express software (Applied biosciences) exclusively matching
the ORF of the indicated genes (listed in table S1).
Data Analysis
The data was normalized and replicates were combined using a
weighted average method as described previously [52]. The log 2
ratio of each spot of combined datasets was then converted to Z-
score, similar to Hogan et al. [55] to circumvent the large
differences in the immunoprecipitation efficiencies of the different
factors. Visual inspection of the Z-scores was carried out on the
UCSC Genome Browser (http://genome.ucsc.edu/). All data
analyses described here were done using data from protein-coding
genes longer than 500 bp. Median Z-score values for promoter and
gene coding sequences were calculated and used in our clustering
analyses. Promoters are defined as the shortest of either 250 bp or
half the intergenic region (half-IG) relative to the reference gene’s 59
boundary. Self-organizing map (SOM) clustering was done with the
Cluster software [33] and visualized with Java Treeview [56]. Only
genes withno missing value wereused for clustering. Gene mapping
was performed as in Rufiange et al. [57] on selected groups of genes
described in the text. Briefly, data were mapped onto the 59 and 39
boundaries in 50 bp windows for each half-gene and adjacent half-
IG regions. A sliding window of 300 bp was then applied to the Z-
scores to smooth the curve.
GO analyses on clusters were performed with funcassociate 2.0.
For this, an association file for the entire gene set was generated
and used for all analyses [34].
Regression analysis was plotted using excel, where the x-axis
and y-axis contained the whole data set of the average ORF
enrichments of the indicated ChIP. A trend line was plotted and
the R
2 was calculated.
Phenotype analysis of rrd1D mutants
The H2O2 survival curves were performed as described
previously [58], briefly exponentially growing cells were washed
once in 50 mM KPO4 (p H7.5) and treated with the indicated
concentration of H2O2 (Bio basic Inc) in 50 mM KPO4 (pH 7.5)
buffer for one hour. Cells were then scored for colony formation
after three days at 30 C on YPD agar.
Spottest with NaAs and 6-azauracil (Sigma) analysis was
performed as described previously [59]. For 6-azauracil strains
were transformed with and empty vector bearing the URA3 gene
(pTW423) and spotted onto synthetic media agar plates lacking
uracil. For lacZ expression the plasmid bearing the ACR3-LacZ
fusion was transformed into strains and exponentially growing cells
were treated with 1 mM NaAs (Sigma), aliquots were taken and
the b-gal assay was performed as described in [39,60].
mRNA extraction and GeXP analysis
Overnight cultures were sub-cultured and grown to an OD600 of
0.6–0.8. Cells were then treated with the indicated drugs for
30 minutes (0.6 mM H2O2, 1 mM NaAs and 100 ng/ml
rapamycin). For heat shock, cells were spun down and
resuspended in preheated media at 37uC for 30 min. mRNA
extraction was performed with the RNeasy extraction kit (Qiagen),
following user guide lines.
Multiplex analysis by GeXP system
Primer design of the set of 10 genes (see suppl. Table S1) was
done using the eXpress Designer module of the express Profiler
software (Beckman Coulter). 25 ng RNA were used in a 20 mL
reaction volume for RT. Kanamycin RNA, an internal positive
control was included. The RT reaction was performed using the
GenomeLab
TM GeXP Start Kit (Beckman Coulter) under the
conditions: 1 min at 48uC, 60 min at 42uC, 5 min at 95uC, hold at
4uC, in a thermal cycler. After the RT, a PCR was performed
under the conditions: 10 min at 95uC, followed by 35 cycles of
30 s at 94uC, 30 s at 55uC, and 1 min at 70uC. Expression analysis
was carried out with the GenomeLab
TM GeXP system (Beckman-
Coulter) following manufacturer’s instructions using the fragment
analysis method. The data was normalized to Kanamycin before
being expressed as a log 2 ratio.
Statistical analysis
For Q-PCR, survival curves and lacZ expression analysis at least
three independent experiments were performed and the standard
deviation and P-values were calculated (Student’s T-test).
For GeXP analysis the percentage CV was calculated for each
replicate. Only % CV #20% was taken for analysis. Values.2S D
were excluded before final calculation.
Supporting Information
Table S1 A list of all primers used for the GeXP and Q-PCR
analysis.
(TIF)
File S1 GO analysis of figures 2A.
(XLS)
Figure S1 (A) A complement to Figure 2C, same experiment
besides that the data was obtained from rapamycin treated cells.
(B) A complement of Fig. 2D, the same experiment besides that
the data was obtained from rapamycin treated cells.
(TIF)
Figure S2 (A) Contains the mapping analysis of Ser5-P and
Ser2-P of rapamycin unaffected genes (cluster W2 and W5). (B)
Mapping of Ser5-P and Ser2-P on clusters S1–S4 from figure 4B.
(TIF)
Figure S3 Comparison of GeXP mRNA expression and
RNAPII median average ChIP data of the corresponding gene
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expressed in log2 ratio.
(TIF)
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